Status:
WITHDRAWN
Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study
Lead Sponsor:
Dr. Michael Dunn
Conditions:
Bronchopulmonary Dysplasia
Eligibility:
All Genders
14-42 years
Phase:
PHASE2
Brief Summary
Bronchopulmonary dysplasia (BPD) is one of the most important morbidities of preterm infants with a high incidence and significant impact on resource utilization and long-term outcome. Systemic cortic...
Eligibility Criteria
Inclusion
- Spontaneous breathing preterm Infants on day 14 to day 42 of age
- Born at \< 30 0/7 weeks gestational age
- Requiring FiO2 ≥ 25% on CPAP including biphasic CPAP or high flow nasal canula
Exclusion
- Presence of chromosomal defects or major congenital anomalies
- Presence of severe infections including sepsis, meningitis, pneumonia, systemic fungal infections
- History of administration of systemic corticosteroids for pulmonary problems, not including that for hypotension
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01895075
Start Date
January 1 2019
End Date
September 1 2020
Last Update
August 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5